Given what we believe management has recently told us about their direction, I am less inclined to think any CEO has to garner respect of regulators, because any company that CYDY partners with will most likely already have those people, as well as the people who understand the science behind leronlimab and what its potential is and how to maximize it as quickly and efficiently as possible.

The skeleton crew left at CYDY will be in line for nice paydays if the partnership(s) go as we hope they will, but will have little to do with any day to day operations once said partership(s) are in place.

Thoughts?